HC Wainwright Issues Pessimistic Outlook for PVLA Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Analysts at HC Wainwright cut their Q1 2025 EPS estimates for Palvella Therapeutics in a research report issued on Tuesday, April 1st. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($3.56) per share for the quarter, down from their prior estimate of ($0.86). HC Wainwright has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ Q1 2025 earnings at ($3.56) EPS, Q2 2025 earnings at ($3.79) EPS, Q2 2025 earnings at ($3.79) EPS, Q3 2025 earnings at ($4.05) EPS, Q4 2025 earnings at ($4.33) EPS, Q4 2025 earnings at ($4.33) EPS, FY2025 earnings at ($15.73) EPS, FY2025 earnings at ($15.73) EPS, FY2026 earnings at ($12.67) EPS, FY2026 earnings at ($12.67) EPS, FY2027 earnings at ($13.80) EPS, FY2027 earnings at ($13.80) EPS, FY2028 earnings at ($8.72) EPS, FY2028 earnings at ($8.72) EPS and FY2029 earnings at ($5.23) EPS.

A number of other research firms have also recently issued reports on PVLA. Canaccord Genuity Group reiterated a “buy” rating and set a $39.00 target price on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Cantor Fitzgerald began coverage on Palvella Therapeutics in a report on Wednesday, December 18th. They set an “overweight” rating for the company. Scotiabank assumed coverage on Palvella Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 target price on the stock. TD Cowen assumed coverage on Palvella Therapeutics in a research report on Wednesday, February 5th. They set a “buy” rating and a $44.00 price target for the company. Finally, Stifel Nicolaus initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, March 26th. They issued a “buy” rating and a $45.00 price objective on the stock. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $43.50.

Palvella Therapeutics Trading Down 1.8 %

Shares of NASDAQ:PVLA opened at $23.98 on Friday. The firm has a market capitalization of $264.24 million, a price-to-earnings ratio of -1.98 and a beta of 0.10. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $29.27. The stock’s fifty day moving average is $21.48.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in PVLA. BML Capital Management LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter valued at $506,000. Frazier Life Sciences Management L.P. bought a new position in shares of Palvella Therapeutics in the 4th quarter valued at about $7,847,000. Cresset Asset Management LLC acquired a new position in shares of Palvella Therapeutics during the 4th quarter worth about $251,000. Suvretta Capital Management LLC acquired a new position in shares of Palvella Therapeutics during the 4th quarter worth about $8,574,000. Finally, DAFNA Capital Management LLC bought a new stake in shares of Palvella Therapeutics in the 4th quarter valued at about $857,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.